Mydrane

Lidocaine Hydrochloride, Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydrane, are local anesthetic, alpha‑adrenergic agonist and antimuscarinic agents, presented as an intracameral solution for intracameral use. They provide intraoperative pupil dilation and ocular anesthesia during cataract surgery in adult patients.

GNH USA supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, surgical centres and ophthalmology clinics worldwide. The product complies with EU regulatory standards and is distributed under strict quality‑assured conditions to meet the needs of eye‑care providers.

Mydrane is employed in ophthalmic procedures to achieve rapid pupil dilation and intraocular anesthesia.

- Cataract surgery: provides rapid pupil dilation and intraocular anesthesia for safe lens removal. - Intraocular lens implantation: facilitates adequate mydriasis and analgesia during lens placement. - Other ocular surgeries: enables pupil dilation and anesthesia for procedures such as trabeculectomy or vitrectomy.

Mydrane may cause a range of ocular and systemic reactions following intracameral administration.

Common Side Effects: - Transient ocular pain or discomfort. - Mild conjunctival redness. - Temporary increase in intraocular pressure. - Blurred vision lasting a few minutes. - Headache. - Nausea.

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, anaphylaxis). - Persistent mydriasis leading to photophobia. - Corneal edema or endothelial damage. - Retinal toxicity. - Systemic lidocaine toxicity (central nervous system or cardiac effects). - Severe hypotension or hypertension from phenylephrine imbalance.

Prior to using Mydrane, clinicians should observe several safety measures.

- Assess patient allergy: verify no known hypersensitivity to lidocaine, phenylephrine or tropicamide. - Monitor intraocular pressure: check IOP before and after injection. - Use appropriate dose: administer only by a qualified ophthalmic surgeon. - Avoid in patients with narrow‑angle glaucoma: risk of angle‑closure crisis. - Avoid in patients with severe cardiovascular disease: phenylephrine may raise blood pressure. - Store at ambient temperature: keep in original container, protect from light and moisture.

Mydrane can interact with other medications that affect ocular or systemic physiology.

Major Interactions (Avoid): - MAO inhibitors: phenylephrine may precipitate hypertensive crisis. - Beta‑blockers: may potentiate ocular hypotensive effects. - Systemic anesthetics: lidocaine may increase risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: additive mydriasis. - Alpha‑adrenergic agonists: additive cardiovascular effects. - Other ocular vasoconstrictors: increased risk of ocular ischemia.